scholarly journals Delayed autism spectrum disorder recognition in children and adolescents previously diagnosed with attention-deficit/hyperactivity disorder

Autism ◽  
2018 ◽  
Vol 23 (4) ◽  
pp. 1065-1072 ◽  
Author(s):  
Vasiliki Kentrou ◽  
Danielle MJ de Veld ◽  
Kawita JK Mataw ◽  
Sander Begeer

Phenotypic elements of autism spectrum disorder can be masked by attention-deficit/hyperactivity disorder symptoms, potentially leading to a misdiagnosis or delaying an autism spectrum disorder diagnosis. This study explored differences in the age of autism spectrum disorder diagnosis between participants with previously diagnosed attention-deficit/hyperactivity disorder versus autism spectrum disorder–only respondents. Children and adolescents, but not adults, initially diagnosed with attention-deficit/hyperactivity disorder received an autism spectrum disorder diagnosis an average of 1.8 years later than autism spectrum disorder–only children, although the findings regarding the adult sample should be interpreted with caution. Gender differences were also explored, revealing that the delay in receiving an autism diagnosis was 1.5 years in boys and 2.6 years in girls with pre-existing attention-deficit/hyperactivity disorder, compared with boys and girls without prior attention-deficit/hyperactivity disorder. No significant gender differences were observed in the adult sample. We argue that overlapping symptoms between autism spectrum disorder and attention-deficit/hyperactivity disorder might delay a formal diagnosis of autism either by leading to a misdiagnosis of attention-deficit/hyperactivity disorder or by making it difficult to identify the presence of co-occurring autism spectrum disorder conditions once an initial diagnosis of attention-deficit/hyperactivity disorder has been obtained. Current findings highlight the need to recruit multidimensional and multidisciplinary screening procedures to assess for potential emerging autism spectrum disorder hallmarks in children and adolescents diagnosed or presenting with attention-deficit/hyperactivity disorder symptoms.

2018 ◽  
Vol 8 (2) ◽  
pp. 107
Author(s):  
Carmen Berenguer ◽  
Belen Rosello ◽  
Geraldine Leader

Autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) are two of the most common childhood-onset neurodevelopmental disorders. Literature has shown different patterns of deficits in executive functioning in children with ASD and ADHD. To date few studies have examined executive functions in both ASD and ADHD and with mixed results.The current study provides the first systematic review to explore distinct executive function components (attention problems, response inhibition, working memory, planning and flexibility) that underlie the specific deficits seen in children and adolescents with both ASD and ADHD disorders. Findings provide evidence for executive dysfunctions across different key components such as attention, response inhibition and verbal working memory in children and adolescents with ASD and comorbid ADHD clinical symptoms. This research explores the neurocognitive profile of the comorbid condition, which is also critical for designing appropriate interventions.


2017 ◽  
Vol 5 (2) ◽  
pp. 39-46 ◽  
Author(s):  
Milena Pereira Pondé ◽  
Mirella Lins Matos ◽  
Cinthia Cristina Pinto Bispo de Oliveira

Aim:  To estimate the prevalence of attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder (ODD) and conduct disorder (CD) in children and adolescents previously diagnosed with autism spectrum disorder (ASD). Methods:  A cross-sectional study involving 71 children and adolescents previously diagnosed by a psychiatrist as having ASD.  All were enrolled at a school that accompanies only individuals with ASD.  The evaluation instruments consisted of a sociodemographic questionnaire and the Brazilian version of the semi-structured interview Kiddie-SADS-PL for the investigation of psychiatric disorders in children and adolescents.  Results:  Overall, 62% of the children in the sample had some psychiatric comorbidity: 49.3% had some form of ADHD, 11.3% ODD and 1.4% CD.   In relation to the children with ADHD, 11.3% fulfilled the criteria for the inattentive subtype, 12.7% for the hyperactive/impulsive subtype, 7.1% for the combined subtype and 18.3% for ADHD not otherwise specified.  Conclusion:  These results ratify the clinical heterogeneity of ASD and highlight the importance of diagnosing comorbidities that could affect the clinical status and functioning level of children and adolescents with ASD.


Author(s):  
Karen Bearss ◽  
Aaron J. Kaat

This chapter will review the available evidence on individuals with co-occurring diagnoses of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). This chapter contends that children diagnosed with both disorders (ASD+ADHD) are a subset of the ASD population that is at risk for delayed recognition of their ASD diagnosis, poor treatment response, and poorer functional outcomes compared to those with ASD without ADHD. Specifically, the chapter highlights the best estimates of the prevalence of the comorbidity, the developmental trajectory of people with co-occurring ASD and ADHD, how ADHD symptoms change across development, overlapping genetic and neurobiological risk factors, psychometrics of ADHD diagnostic instruments in an ASD population, neuropsychological and functional impairments associated with co-occurring ASD and ADHD, and the current state of evidence-based treatment for both ASD and ADHD symptoms. Finally, the chapter discusses fruitful avenues of research for improving understanding of this high-risk comorbidity so that mechanism-to-treatment pathways for ADHD in children with ASD can be better developed.


2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Viktoria Johansson ◽  
Sven Sandin ◽  
Zheng Chang ◽  
Mark J. Taylor ◽  
Paul Lichtenstein ◽  
...  

Abstract Background Clinical studies found that medication for attention-deficit/hyperactivity disorder (ADHD) is effective in coexisting autism spectrum disorder (ASD), but current research is based on small clinical studies mainly performed on children or adolescents. We here use register data to examine if individuals with ADHD and coexisting ASD present differences in the prescribing patterns of ADHD medication when compared to individuals with pure ADHD. Methods Data with information on filled prescriptions and diagnoses was retrieved from the Swedish Prescribed Drug Register and the National Patient Register. We identified 34,374 individuals with pure ADHD and 5012 individuals with ADHD and coexisting ASD, aged between 3 and 80 years. The first treatment episode with ADHD medications (≥ 2 filled prescriptions within 90 days) and daily doses of methylphenidate during a 3-year period was measured. Odds ratios (ORs) were calculated for the likelihood of being prescribed ADHD medication in individuals with and without ASD and Wilcoxon rank-sum test was used to compare group differences in dose per day. Results Individuals with ADHD and coexisting ASD were less likely to start continuous treatment with ADHD medication (ADHD 80.5%; ADHD with ASD 76.2%; OR, 0.80; 95% confidence interval, 0.75-0.86), were less likely to be prescribed methylphenidate, and were more commonly prescribed second line treatments such as dexamphetamine, amphetamine, or modafinil. No group difference was observed for atomoxetine. In adults with ADHD and coexisting ASD, methylphenidate was prescribed in lower daily doses over three years as compared to individuals with pure ADHD. Conclusions The findings indicate that there are differences in the medical treatment of individuals with or without ASD. If these differences are due to different medication responses in ASD or due to other factors such as clinicians’ perceptions of medication effects in patients with ASD, needs to be further studied.


Sign in / Sign up

Export Citation Format

Share Document